Bide Pharmatech (SH:688073) Xin Lang Zheng Quan·2025-11-04 01:59Core Viewpoint - Bid Pharma's stock price has experienced fluctuations, with a year-to-date increase of 49.79% but a recent decline of 7.01% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Bid Pharma achieved a revenue of 979 million yuan, representing a year-on-year growth of 20.67% [2] - The net profit attributable to shareholders for the same period was 120 million yuan, showing a year-on-year increase of 42.79% [2] Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 7.64% to 3,493, while the average circulating shares per person increased by 8.27% to 12,377 shares [2] - The company has distributed a total of 258 million yuan in dividends since its A-share listing [3] Institutional Holdings - As of September 30, 2025, notable institutional shareholders include: - China Europe Medical Health Mixed A (003095) as the second-largest shareholder with 4.4532 million shares, an increase of 200,700 shares from the previous period [3] - China Europe Medical Innovation Stock A (006228) as a new fourth-largest shareholder with 2.0222 million shares [3] - Other new institutional shareholders include E Fund Value Growth Mixed (110010), ICBC Medical Health Stock (000831), and others [3] Company Overview - Bid Pharma, established on April 27, 2007, and listed on October 11, 2022, focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The company's revenue composition includes: - 43.26% from molecular building block heterocyclic compounds - 23.32% from molecular building block aromatic compounds - 16.36% from molecular building block aliphatic compounds - 10.57% from catalysts and ligands - 6.49% from life science reagents [1] Market Position - Bid Pharma is categorized under the pharmaceutical and biological industry, specifically in medical services and medical research outsourcing [1] - The company is associated with several concept sectors, including high dividend yield, financing, and small-cap stocks [1]